2016 - Fellow of the Indian National Academy of Engineering (INAE)
His main research concerns Biochemistry, Chromatography, Drug carrier, Protein aggregation and Microsphere. His work deals with themes such as Antibody and Isotonic, which intersect with Biochemistry. Jeffrey L. Cleland has researched Chromatography in several fields, including Trehalose, Polyethylene glycol and Diluent.
Drug carrier is a primary field of his research addressed under Pharmacology. His Protein aggregation research includes themes of Crystallography, Biophysics, Denaturation and Infrared spectroscopy. His Microsphere research incorporates elements of Human growth hormone and Active ingredient.
Jeffrey L. Cleland spends much of his time researching Biochemistry, Pharmacology, Chromatography, In vivo and PLGA. His studies deal with areas such as Biophysics and Microsphere as well as Biochemistry. His Chromatography study integrates concerns from other disciplines, such as Sucrose, Polysorbate 20, Antibody and Isotonic.
Within one scientific family, Jeffrey L. Cleland focuses on topics pertaining to Endocrinology under In vivo, and may sometimes address concerns connected to Growth factor. His studies in PLGA integrate themes in fields like Adjuvant and Drug carrier, Drug delivery. The various areas that Jeffrey L. Cleland examines in his Drug carrier study include Liberation and Dosage form.
Sunitinib, Pharmacology, Biomedical engineering, Dendrimer and In vivo are his primary areas of study. His study on Sunitinib also encompasses disciplines like
His Biomedical engineering research focuses on Microparticle and how it relates to Extended release. His In vivo research incorporates themes from Hormone, Receptor, Potency and Pharmacodynamics. Biochemistry is frequently linked to Vascular endothelial growth factor in his study.
Jeffrey L. Cleland mainly focuses on Sunitinib, Choroid, Ophthalmology, In vivo and Macular degeneration. He interconnects Medical therapy, Pharmacokinetics, Biomedical engineering and Microparticle in the investigation of issues within In vivo. He has included themes like Endocrinology and Growth hormone deficiency in his Pharmacokinetics study.
His Macular degeneration research is multidisciplinary, relying on both Polymeric matrix, Solvent system, Corneal neovascularization, Controlled release and Cytotoxicity. He regularly ties together related areas like Pharmacology in his Cytotoxicity studies. His research combines Potency and Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover
John Street;Min Bao;Leo deGuzman;Stuart Bunting.
Proceedings of the National Academy of Sciences of the United States of America (2002)
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.
Cleland Jl;Powell Mf;Shire Sj.
Critical Reviews in Therapeutic Drug Carrier Systems (1993)
A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody
Jeffrey L. Cleland;Xanthe Lam;Brent Kendrick;Janet Yang.
Journal of Pharmaceutical Sciences (2001)
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Volker Schellenberger;Chia-wei Wang;Nathan C Geething;Benjamin J Spink.
Nature Biotechnology (2009)
A month-long effect from a single injection of microencapsulated human growth hormone.
OluFunmi L. Johnson;Jeffrey L. Cleland;Hye Jung Lee;Margarita Charnis.
Nature Medicine (1996)
Stable Formulations of Recombinant Human Growth Hormone and Interferon-γ for Microencapsulation in Biodegradable Mircospheres
Jeffrey L. Cleland;Andrew J. S. Jones.
Pharmaceutical Research (1996)
Stabile isotonic lyophilized protein formulation
Shire Steven J;Andya James;Cleland Jeffrey L;Hsu Chung C.
Antioxidants for Prevention of Methionine Oxidation in Recombinant Monoclonal Antibody HER2
Xanthe M. Lam;Janet Y. Yang;Jeffrey L. Cleland.
Journal of Pharmaceutical Sciences (1997)
Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions
Narendra B. Bam;Jeffrey L. Cleland;Janet Yang;Mark C. Manning.
Journal of Pharmaceutical Sciences (1998)
The stabilization and encapsulation of human growth hormone into biodegradable microspheres
OluFunmi L. Johnson;Warren Jaworowicz;Jeffrey L. Cleland;Leonie Bailey.
Pharmaceutical Research (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: